JP2019532017A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019532017A5 JP2019532017A5 JP2019501628A JP2019501628A JP2019532017A5 JP 2019532017 A5 JP2019532017 A5 JP 2019532017A5 JP 2019501628 A JP2019501628 A JP 2019501628A JP 2019501628 A JP2019501628 A JP 2019501628A JP 2019532017 A5 JP2019532017 A5 JP 2019532017A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- bdc
- group
- group comprises
- epitopes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102100024952 Protein CBFA2T1 Human genes 0.000 claims 45
- 206010028980 Neoplasm Diseases 0.000 claims 39
- 201000011510 cancer Diseases 0.000 claims 37
- 239000000427 antigen Substances 0.000 claims 33
- 102000036639 antigens Human genes 0.000 claims 33
- 108091007433 antigens Proteins 0.000 claims 33
- 210000002865 immune cell Anatomy 0.000 claims 29
- 230000003213 activating effect Effects 0.000 claims 27
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 22
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 22
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 19
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 19
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 17
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 17
- 230000008685 targeting Effects 0.000 claims 17
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims 13
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims 13
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims 13
- 230000003252 repetitive effect Effects 0.000 claims 9
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 8
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims 8
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims 8
- -1 Lewis Y Proteins 0.000 claims 8
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 8
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 6
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims 5
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 4
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 4
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 4
- 101000621309 Homo sapiens Wilms tumor protein Proteins 0.000 claims 3
- 102000003735 Mesothelin Human genes 0.000 claims 3
- 108090000015 Mesothelin Proteins 0.000 claims 3
- 102100022748 Wilms tumor protein Human genes 0.000 claims 3
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 2
- 101001098352 Homo sapiens OX-2 membrane glycoprotein Proteins 0.000 claims 2
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 2
- 102000017578 LAG3 Human genes 0.000 claims 2
- 102100037589 OX-2 membrane glycoprotein Human genes 0.000 claims 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 2
- 101001051488 Takifugu rubripes Neural cell adhesion molecule L1 Proteins 0.000 claims 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 2
- 102000006815 folate receptor Human genes 0.000 claims 2
- 108020005243 folate receptor Proteins 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 210000000822 natural killer cell Anatomy 0.000 claims 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 1
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 1
- 108700012439 CA9 Proteins 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 102100035793 CD83 antigen Human genes 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 1
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 102100025390 Integrin beta-2 Human genes 0.000 claims 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 1
- 102100040120 Prominin-1 Human genes 0.000 claims 1
- 102100038081 Signal transducer CD24 Human genes 0.000 claims 1
- 229940126530 T cell activator Drugs 0.000 claims 1
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- 108700020467 WT1 Proteins 0.000 claims 1
- 102000040856 WT1 Human genes 0.000 claims 1
- 101150084041 WT1 gene Proteins 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 230000004075 alteration Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229940022353 herceptin Drugs 0.000 claims 1
- 230000005931 immune cell recruitment Effects 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 229960002450 ofatumumab Drugs 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662362397P | 2016-07-14 | 2016-07-14 | |
| US62/362,397 | 2016-07-14 | ||
| US201762480230P | 2017-03-31 | 2017-03-31 | |
| US62/480,230 | 2017-03-31 | ||
| PCT/US2017/042264 WO2018014001A1 (en) | 2016-07-14 | 2017-07-14 | Multiple bi-specific binding domain constructs with different epitope binding to treat cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019532017A JP2019532017A (ja) | 2019-11-07 |
| JP2019532017A5 true JP2019532017A5 (enExample) | 2020-08-20 |
Family
ID=60952209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019501628A Withdrawn JP2019532017A (ja) | 2016-07-14 | 2017-07-14 | がんを治療するための異なるエピトープ結合を示す複数の二重特異性結合ドメイン構築物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20190233534A1 (enExample) |
| EP (1) | EP3484516A4 (enExample) |
| JP (1) | JP2019532017A (enExample) |
| AU (1) | AU2017297603A1 (enExample) |
| CA (1) | CA3030841A1 (enExample) |
| WO (1) | WO2018014001A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018218207A1 (en) * | 2017-05-26 | 2018-11-29 | Fred Hutchinson Cancer Research Center | Anti-cd33 antibodies and uses thereof |
| CN112351820B (zh) * | 2018-06-21 | 2024-10-11 | 瑞泽恩制药公司 | 双特异性抗psma x抗cd28抗体及其用途 |
| SG11202105093RA (en) * | 2018-12-21 | 2021-06-29 | Hoffmann La Roche | Tumor-targeted agonistic cd28 antigen binding molecules |
| CN109485734B (zh) * | 2018-12-30 | 2020-05-12 | 广州百暨基因科技有限公司 | 一种靶向bcma和cd19的双特异性嵌合抗原受体及其应用 |
| WO2020150513A1 (en) * | 2019-01-17 | 2020-07-23 | Fred Hutchinson Cancer Research Center | Methods to enhance the selectivity and effectiveness of cancer treatments |
| BR112021019915A2 (pt) * | 2019-04-09 | 2021-12-07 | Sanofi Sa | Proteínas de ligação triespecíficas, métodos e usos dos mesmos |
| US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
| BR112021022682A2 (pt) | 2019-05-14 | 2022-02-22 | Provention Bio Inc | Métodos e composições para prevenir diabetes do tipo 1 |
| UY38701A (es) | 2019-05-21 | 2020-12-31 | Novartis Ag | Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas |
| EP3990022A4 (en) * | 2019-06-26 | 2023-06-28 | Memorial Sloan Kettering Cancer Center | Anti-cd33 antibodies for treating cancer |
| AU2020306772A1 (en) * | 2019-06-27 | 2022-02-17 | Verseau Therapeutics, Inc. | Anti-LRRC25 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof |
| WO2021202793A2 (en) * | 2020-03-31 | 2021-10-07 | Fred Hutchinson Cancer Research Center | Chimeric antigen receptors targeting cd33 |
| CN115397515A (zh) * | 2020-03-31 | 2022-11-25 | 弗莱德哈钦森癌症中心 | 人抗cd33抗体和其用途 |
| WO2021202726A2 (en) * | 2020-03-31 | 2021-10-07 | Fred Hutchinson Cancer Research Center | Anti-cd33 antibodies and uses thereof |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| EP4200332A1 (en) | 2020-08-19 | 2023-06-28 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
| WO2022094299A2 (en) * | 2020-10-30 | 2022-05-05 | Janux Therapeutics, Inc. | Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof |
| US20240392003A1 (en) * | 2021-02-02 | 2024-11-28 | Numab Therapeutics AG | Multispecific antibodies having specificity for ror1 and cd3 |
| EP4482585A1 (en) | 2022-02-23 | 2025-01-01 | Xencor, Inc. | Anti-cd28 x anti-psma antibodies |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP0575545B1 (en) | 1991-03-15 | 2003-05-21 | Amgen Inc. | Pegylation of polypeptides |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993016185A2 (en) | 1992-02-06 | 1993-08-19 | Creative Biomolecules, Inc. | Biosynthetic binding protein for cancer marker |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| WO2000047625A2 (en) | 1999-02-12 | 2000-08-17 | Genetics Institute, Inc. | Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith |
| JP4093757B2 (ja) | 1999-08-24 | 2008-06-04 | メダレックス， インコーポレイテッド | ヒトｃｔｌａ−４抗体およびその使用 |
| US7034121B2 (en) | 2000-01-27 | 2006-04-25 | Genetics Institue, Llc | Antibodies against CTLA4 |
| EP1354600A1 (en) | 2002-04-19 | 2003-10-22 | Affimed Therapeutics AG | Antibody combination useful for tumor therapy |
| AU2004253770C1 (en) | 2003-07-02 | 2010-04-15 | Innate Pharma | PAN-KIR2DL NK-receptor antibodies and their use in diagnostik and therapy |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| DK1791865T3 (da) | 2004-06-29 | 2010-11-01 | Immunocore Ltd | Celler der udtrykker en modificeret T-cellerecptor |
| DE602006003695D1 (de) | 2005-01-05 | 2009-01-02 | F Star Biotech Forsch & Entw | Synthetische Immunoglobulindomänen mit in Regionen des Moleküls, die sich von den die Komplementarität bestimmenden Bereichen unterscheiden, modifizierten Bindeeigenschaften |
| CA2970873C (en) | 2005-05-09 | 2022-05-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| WO2008103849A2 (en) | 2007-02-21 | 2008-08-28 | The Regents Of The University Of California | Methods and compounds for lymphoma cell detection and isolation |
| EP1829895A1 (en) | 2006-03-03 | 2007-09-05 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies |
| US8247537B2 (en) | 2006-11-15 | 2012-08-21 | Medarex, Inc. | Human monoclonal antibodies to BTLA and methods of use |
| WO2008076868A2 (en) | 2006-12-18 | 2008-06-26 | Abbott Laboratories | Methods and compositions related to modulation of receptor tyrosine kinase orphan receptor-1 (ror-1) |
| US8163279B2 (en) | 2007-04-13 | 2012-04-24 | Stemline Therapeutics, Inc. | IL3Rα antibody conjugates and uses thereof |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| JP5841332B2 (ja) | 2008-07-18 | 2016-01-13 | 国立大学法人名古屋大学 | 細胞増殖阻害剤 |
| BRPI0919377A2 (pt) | 2008-09-26 | 2016-09-27 | Dana Farber Cancer Inst Inc | anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento |
| WO2010065939A1 (en) | 2008-12-05 | 2010-06-10 | Indiana University Research & Technology Corporation | Combination therapy to enhace nk cell mediated cytotoxicty |
| FI4209510T3 (fi) | 2008-12-09 | 2024-03-22 | Hoffmann La Roche | Anti-PD-L1-vasta-aineita ja niiden käyttö T-solutoiminnan tehostamiseksi |
| AU2010230563A1 (en) | 2009-04-02 | 2011-09-22 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain Fab fragments |
| US20100256340A1 (en) | 2009-04-07 | 2010-10-07 | Ulrich Brinkmann | Trivalent, bispecific antibodies |
| CA2759733C (en) | 2009-04-23 | 2019-09-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-human ror1 antibodies |
| RU2570633C2 (ru) | 2009-05-27 | 2015-12-10 | Ф.Хоффманн-Ля Рош Аг | Три- или тетраспецифические антитела |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
| US20120282177A1 (en) | 2009-11-02 | 2012-11-08 | Christian Rohlff | ROR1 as Therapeutic and Diagnostic Target |
| DK2513146T3 (en) | 2009-12-18 | 2017-07-31 | Kancera Ab | Antibodies against ROR1 capable of inducing cell death by CLL |
| TW201125583A (en) * | 2009-12-23 | 2011-08-01 | Bioalliance Cv | Anti-EpCAM antibodies that induce apoptosis of cancer cells and methods using same |
| WO2011100538A1 (en) | 2010-02-11 | 2011-08-18 | Alexion Pharmaceuticals, Inc. | Therapeutic methods using an ti-cd200 antibodies |
| WO2011159847A2 (en) | 2010-06-15 | 2011-12-22 | The Regents Of The University Of California | Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof |
| EP3828205A1 (en) | 2010-10-01 | 2021-06-02 | Oxford BioTherapeutics Ltd | Anti-ror1 antibodies |
| PL2632954T5 (pl) * | 2010-10-27 | 2021-11-02 | Amgen Research (Munich) Gmbh | Środki i sposoby leczenia DLBCL |
| ES2657970T3 (es) * | 2010-12-01 | 2018-03-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anticuerpos contra ROR1 de conejo/ser humano quiméricos |
| GB201020995D0 (en) | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
| ES2634098T3 (es) | 2011-01-14 | 2017-09-26 | The Regents Of The University Of California | Anticuerpos terapéuticos contra la proteína ROR-1 y procedimientos para el uso de los mismos. |
| US20140242081A1 (en) * | 2011-07-18 | 2014-08-28 | Micromet Ag | Dosing regimens for treatment of cea-expressing cancers |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| BR112015002816A8 (pt) * | 2012-08-20 | 2023-04-18 | Hutchinson Fred Cancer Res | Método e composições para imunoterapia celular |
| US20140302037A1 (en) * | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| US20140308285A1 (en) | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
| EP2789630A1 (en) * | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| CN114163529B (zh) | 2013-12-24 | 2024-12-13 | 杨森制药公司 | 抗vista抗体及片段 |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| PE20170765A1 (es) * | 2014-05-29 | 2017-07-04 | Macrogenics Inc | Moleculas de union tri-especificas y metodos de uso de las mismas |
| BR112017011092A2 (pt) * | 2014-11-26 | 2017-12-26 | Xencor Inc | anticorpos heterodiméricos que ligam cd3 e antígenos de tumor |
-
2017
- 2017-07-14 AU AU2017297603A patent/AU2017297603A1/en not_active Abandoned
- 2017-07-14 EP EP17828588.8A patent/EP3484516A4/en active Pending
- 2017-07-14 JP JP2019501628A patent/JP2019532017A/ja not_active Withdrawn
- 2017-07-14 WO PCT/US2017/042264 patent/WO2018014001A1/en not_active Ceased
- 2017-07-14 US US16/317,782 patent/US20190233534A1/en not_active Abandoned
- 2017-07-14 CA CA3030841A patent/CA3030841A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019532017A5 (enExample) | ||
| JP7573441B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| US11202828B2 (en) | Therapeutic SIRP-α antibodies | |
| HRP20211333T1 (hr) | Molekule za vezanje pd-1 i lag-3 i postupci za njihovu uporabu | |
| JP2020508334A5 (enExample) | ||
| JP2020536543A5 (enExample) | ||
| JP2020530289A5 (enExample) | ||
| JP2018518939A5 (enExample) | ||
| JP2015527070A5 (enExample) | ||
| JP2019513009A5 (enExample) | ||
| JP2018521628A5 (enExample) | ||
| RU2018126297A (ru) | Антитела, нацеленные на cd32b, и способы их применения | |
| JP2020512973A5 (enExample) | ||
| JP2019513725A5 (enExample) | ||
| JP2018533371A5 (enExample) | ||
| JP2016533763A5 (ja) | ヒトｐｄ−１に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物 | |
| JPWO2019033043A5 (enExample) | ||
| CA2936244A1 (en) | Compositions and methods for modulating and redirecting immune responses | |
| RU2017108903A (ru) | Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей | |
| TW201702265A (zh) | 結合lag-3的分子和其使用方法 | |
| JP2017524367A5 (enExample) | ||
| RU2018135247A (ru) | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К CD25 И Fc ГАММА-РЕЦЕПТОРУ ДЛЯ ЭЛИМИНАЦИИ ОПУХОЛЕСПЕЦИФИЧЕСКИХ КЛЕТОК | |
| JP2017500009A5 (enExample) | ||
| RU2019126655A (ru) | Нуклеиновые кислоты, кодирующие химерные рецепторы, полипептидные химерные рецепторы, кодируемые ими, векторы экспрессии, содержащие их, выделенные клетки-хозяева, содержащие их, композиции, содержащие выделенные клетки-хозяева, а также способы получения выделенных клеток-хозяев in vitro, способы выбора нуклеиновых кислот, кодирующих химерные рецепторы, in vitro и способы проведения клеточной иммунотерапии у субъекта, имеющего опухоль | |
| JP2019537449A5 (enExample) |